Pharmaceuticals, Biotechnology and Life Sciences
Sanofi and Lonza will invest €270 million (CHF 290 million) in a mammalian cell culture site for monoclonal antibody production in Swiss town of Visp, planned for opening in 2020.
Ipsen has entered into a definitive agreement to acquire Sanofi’s five consumer healthcare products in certain European territories.
The fourth quarter of 2016, global net sales of Praluent were $41 million, compared to $7 million in the fourth quarter of 2015.
Sanofi and Regeneron will continue marketing, selling and manufacturing Praluent in the United States (U.S.) during their appeal on Amgen’s patent claims.
Sanofi has reported net income of €1,6 billion for Q4 2016 which is 6% down compared to the same period last year. The full year income was €7.3 billion, 0.9% down from the last year.
Zealand Pharma has reported royalty revenue from Sanofi’s sales of Lyxumia (lixisenatide) outside the United States of €0.7 million for Q4 2016 and annual royalty revenue of €3.3 million in 2016.
Sanofi announced on Wednesday two approvals for its drugs in North America. Rheumatoid arthritis drug, which it has made in cooperation with Regeneron Pharmaceuticals, has been approved by Health Canada and the U.S. Food and Drug Administration (FDA) has approved Xyzal Allergy 24HR
Sanofi has appointed Kathleen Tregoning, Biogen’s senior Vice President of Corporate Affairs, as a new member of the Executive Committee, effective February 27, 2017.
Flu, or influenza, is a very contagious, acute, viral respiratory infection. Influenza viruses vary in a high degree. The extent…
For the last year, Sanofi’s chief executive has made clear his quest for deals to help revive the fortunes of France’s biggest drugmaker.
The market is still waiting. Olivier Brandicourt’s failure to land two big biotech acquisitions he was chasing has led to growing impatience among some investors.